- Home
- CDNA vs PHAT Comparison
CDNA vs PHAT Comparison
Compare CDNA & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- PHAT
- Stock Information
- Founded
- CDNA 1998
- PHAT 2018
- Country
- CDNA United States
- PHAT United States
- Employees
- CDNA N/A
- PHAT N/A
- Industry
- CDNA Medical Specialities
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- CDNA Health Care
- PHAT Health Care
- Exchange
- CDNA Nasdaq
- PHAT Nasdaq
- Market Cap
- CDNA 712.2M
- PHAT 820.8M
- IPO Year
- CDNA 2014
- PHAT 2019
- Fundamental
- Price
- CDNA $13.53
- PHAT $11.84
- Analyst Decision
- CDNA Buy
- PHAT Strong Buy
- Analyst Count
- CDNA 8
- PHAT 5
- Target Price
- CDNA $26.86
- PHAT $16.40
- AVG Volume (30 Days)
- CDNA 1.5M
- PHAT 1.1M
- Earning Date
- CDNA 11-03-2025
- PHAT 11-06-2025
- Dividend Yield
- CDNA N/A
- PHAT N/A
- EPS Growth
- CDNA N/A
- PHAT N/A
- EPS
- CDNA 1.00
- PHAT N/A
- Revenue
- CDNA $340,826,000.00
- PHAT $114,039,000.00
- Revenue This Year
- CDNA $13.02
- PHAT $207.52
- Revenue Next Year
- CDNA $12.85
- PHAT $96.46
- P/E Ratio
- CDNA $13.56
- PHAT N/A
- Revenue Growth
- CDNA 14.72
- PHAT 1049.82
- 52 Week Low
- CDNA $10.96
- PHAT $2.21
- 52 Week High
- CDNA $32.97
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- CDNA 52.36
- PHAT 56.48
- Support Level
- CDNA $13.12
- PHAT $11.89
- Resistance Level
- CDNA $13.80
- PHAT $13.00
- Average True Range (ATR)
- CDNA 0.67
- PHAT 0.72
- MACD
- CDNA 0.16
- PHAT -0.10
- Stochastic Oscillator
- CDNA 63.39
- PHAT 33.71
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.